Data updated: Mar 10, 2026
LONHALA MAGNAIR KIT
GLYCOPYRROLATE
Approved 2017-12-05
1
Indication
--
Phase 3 Trials
8
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2017-12-05
- Routes
- INHALATION
- Dosage Forms
- SOLUTION
LONHALA MAGNAIR KIT Approval History
Loading approval history...
What LONHALA MAGNAIR KIT Treats
1 FDA approvalsOriginally approved for its first indication in 2017 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LONHALA MAGNAIR KIT FDA Label Details
ProLONHALA MAGNAIR KIT Patents & Exclusivity
Latest Patent: Dec 2036
Patents (9 active)
US10744277
Expires Dec 7, 2036
US10688518
Expires Nov 12, 2036
US10376661
Expires Sep 14, 2035
US9604018
Expires May 16, 2033
US9168556
Expires Sep 1, 2032
US9789270
Expires Oct 30, 2030
US10940110
Expires Feb 26, 2029
US9265900
Expires Dec 7, 2028
US11278683
Expires Aug 16, 2026
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.